Article

Interlaboratory concordance of DNA sequence analysis to detect reverse transcriptase mutations in HIV-1 proviral DNA. ACTG Sequencing Working Group. AIDS Clinical Trials Group

University of Rochester School of Medicine and Dentistry, NY, USA.
Journal of Virological Methods (Impact Factor: 1.88). 12/1998; 75(1):93-104.
Source: PubMed

ABSTRACT Thirteen laboratories evaluated the reproducibility of sequencing methods to detect drug resistance mutations in HIV-1 reverse transcriptase (RT). Blinded, cultured peripheral blood mononuclear cell pellets were distributed to each laboratory. Each laboratory used its preferred method for sequencing proviral DNA. Differences in protocols included: DNA purification; number of PCR amplifications; PCR product purification; sequence/location of PCR/sequencing primers; sequencing template; sequencing reaction label; sequencing polymerase; and use of manual versus automated methods to resolve sequencing reaction products. Five unknowns were evaluated. Thirteen laboratories submitted 39043 nucleotide assignments spanning codons 10-256 of HIV-1 RT. A consensus nucleotide assignment (defined as agreement among > or = 75% of laboratories) could be made in over 99% of nucleotide positions, and was more frequent in the three laboratory isolates. The overall rate of discrepant nucleotide assignments was 0.29%. A consensus nucleotide assignment could not be made at RT codon 41 in the clinical isolate tested. Clonal analysis revealed that this was due to the presence of a mixture of wild-type and mutant genotypes. These observations suggest that sequencing methodologies currently in use in ACTG laboratories to sequence HIV-1 RT yield highly concordant results for laboratory strains; however, more discrepancies among laboratories may occur when clinical isolates are tested.

Download full-text

Full-text

Available from: Richard Y. Zhao, Sep 03, 2014
0 Followers
 · 
71 Views
 · 
7 Downloads
  • Source
    • "The relative ratio of nonsynonymous and synonymous changes in the HIV env gene seems to be generated by a balance between selective pressure placed on the virus quasispecies mainly by the immune system, which favors amino acid diversification, and the negative selection against missense mutation that breaks the structural constraints of the functional Env protein (Anastassopoulou et al., 2003; Shankarappa et al., 1999). Patients under HAART have been extensively followed for the emergence of drug-resistance by sequencing pol and identifying the associated mutations (Demeter et al., 1998; Gallant et al., 2003; Little et al., 2002; Tirado et al., 2004; Unal et al., 1996). However, there is only limited information available regarding the evolution of other viral genes in patients on HAART. "
    [Show abstract] [Hide abstract]
    ABSTRACT: We analyzed the viral C2-V4 envelope diversity, glycosylation patterns, and dS/dN ratios of plasma HIV-1 in an attempt to better understand the complex interaction between viral quasispecies and the host-selective pressures pre- and post-HAART. Phylogenetic analysis of the envelope gene of five patients revealed monophyletic clustering in patients with higher CD4+ T cell counts and sequence intermingling in those with lower CD4+ T cells in relation to the stage of HAART. Our analyses also showed clear shifts in N-linked glycosylation patterns in patients with higher CD4+ T cells, suggesting possible distinct immunological pressures pre- and post-HAART. The relative preponderance of synonymous/nonsynonymous changes in the envelope region suggested a positive selection in patients with higher CD4+ T cells, whereas lack of evidence for positive selection was found in the patients with lower CD4+ T cells. An exception to the last analysis occurred in the only patient who reached complete viral suppression, maybe due to drug pressure exerted over the pol gene that may obscure the immune pressure/selection at the envelope in this analysis. All these indications may suggest that even when HAART generates viral suppression, quasispecies evolve in the envelope gene probably resulting from host-selective pressure.
    Virology 01/2005; 330(1):116-26. DOI:10.1016/j.virol.2004.09.015 · 3.28 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Eines der Hauptprobleme der antiviralen Therapie ist das Entstehen resistenzassoziierter Mutationen. Der Nachweis solcher Mutationen ist für eine erfolgreiche Therapie eine entscheidende Voraussetzung. In dieser Arbeit wurde ein Microarray zur Detektion von relevanten Mutationen innerhalb der Protease (PR) und –Reversen Transkriptase (RT) des humanen Immundefizienzvirus (HIV) entwickelt und validiert. Als zeit und kostengünstigere Alternative zur routinemäßig eingesetzten Sanger-Sequenzierung wurde die Arrayed Primer Extension (APEX)-Methode zur genotypischen Resistenzbestimmung etabliert. Zur Abfrage von 26 resistenzassoziierten Codons innerhalb der PR- und 33 Codons innerhalb der RT-kodierenden Region wurden Oligonukleotide erstellt. Aufgrund der enormen Variabilität des HIV Genoms berücksichtigen diese alle Sequenzvarianten, die mit einer Frequenz von >5% (PR) bzw. >10% (RT) in der Los Alamos Datenbank verzeichnet sind. Um diese Sequenzabdeckung technisch und finanziell zu realisieren, wurde die Verwendung degenerierter Oligonukleotidsonden für APEX etabliert. Für die Validierung des PR und RT Microarrays wurden 94 bzw. 48 PCR Produkte aus Patientenproben mit bekannter Sequenz analysiert. Dafür wurden die APEX-Reaktionsbedingungen erfolgreich angepasst. Die Vergleichssequenzen wurden durch Sanger-Sequenzierung ermittelt. 93% (PR) bzw. 88% (RT) aller untersuchten Positionen wurden mittels APEX übereinstimmend bestimmt. Der Anteil an Positionen, für die aufgrund schwacher Signalintensitäten keine Sequenzzuweisung vorgenommen werden konnten, liegt bei 3% (PR) und 5% (RT). Es wurde gezeigt, dass dieses Ergebnis durch Optimierung der Sonden deutlich verbessert wird. Die zufällig ausgewählten Proben umfassten sowohl HIV-Subtyp B als auch nicht Subtyp B Sequenzen. Aufgrund der verwendeten Sonden ist die Übereinstimmung für die untersuchten Subtyp B Proben im Vergleich mit den nicht Subtyp B Proben höher (94% / 88% für PR; 88% / 84% für RT). Sequenzmischungen wurden qualitativ gut detektiert, eine Quantifizierung ist aber Sonden-abhängig. Der Fehlerbereich ist vergleichbar mit dem anderer Genotypisierungsmethoden. Das entwickelte Testverfahren kann kostengünstig mit hohem Probendurchsatz durchgeführt werden. Parallel zur HIV-Genotypisierung wurde anhand zweier Beispiele gezeigt, dass auch Mutationen im Wirtsgenom, die mit der Krankheitsprogression assoziiert sind, sehr gut mittels APEX nachgewiesen werden können. Dies wird künftig eine sinnvolle Ergänzung des Microarrays sein und eine individuellere Therapie ermöglichen. Mutations that confer drug resistance are a major obstacle in antiviral therapy. The detection of such mutations in the protease (PR) and reverse transcriptase (RT) of human immunodeficiency virus (HIV) is an important step in the successful treatment of HIV indection. A standard method involved in mutation detection, Sanger sequencing, has proven to be costly and temporally disadvantegous. In order to overcome such inadequacies, a genotypic resistance assay based on APEX has been developed and established. Oligonuceotides were designed for the detection of 26 resistance related codons in PR and 33 codons in RT coding region. Due to the immense sequence heterogeneity of the viral genome, primers were selected to map sequence variants that representing >5% PR and >10% RT in the Los Alamos Sequence Databank. The application of degenerated primers to APEX was successfully established to cover all these sequence combinations. For microarray validation 94 PR and 48 RT patient derived PCR products were analysed. As reference sequences, information of these samples were previously obtained by Sanger sequencing. Concordance between the reference method and APEX was high, at 93% and 88% for PR and RT, respectively. Due to weak signal intensities it was impossible to determine the sequence via primer extension for 3% PR and 5% RT of positions analyzed. Efficiency of detection was improved by modification of the chip layout by optimization of oligonucleotides, demonstrated by means of the protease microarray. The analyzed patient set was randomly chosen und contained HIV-subtype B as well as non-subtype B samples. Currently, non-subtype B samples could be investigated by PR and RT microarrays. Concordance with standard sequencing is lower than for subtype B sequences (88%/94% for PR; 84%/88% for RT). Furthermore the microarrays provided a confident detection of sequence mixtures in a qualitative manner; however quantification is dependent on site-specific oligonucleotides. The developed APEX assay achieves similar results compared with other methods for genotypic resistance testing in HIV. The developed microarrays allow a cost- and time-effective genotypic resistance testing in a high-throughput manner. In addition to HIV resistance testing it is useful to acquire information about several host genes which are involved in the progression to AIDS. For two examples it was shown that relevant mutations can be very well detected by APEX. The parallel analysis of such mutations will enable a more individualized therapy.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A panel (ENVA-1) of well-defined blinded samples containing wild-type and mutant human immunodeficiency virus type 1 (HIV-1) reverse transcriptase was analyzed by automated DNA sequencing in 23 laboratories worldwide. Drug resistance mutations at codons 41, 215, and 184 were present in the panel samples at different ratios to the wild type. The presence of mutant genotypes was determined qualitatively and quantitatively. All laboratories reported the presence of sequence heterogeneities at codons 41, 215, and 184 in one or more of the panel samples, though not all reported the correct codon genotypes. Two laboratories reported a mutant genotype in samples containing only the wild type, whereas two and three laboratories failed to detect the mutant genotypes at codons 41 and 215, respectively, in a completely mutant DNA population. Mutations present at relative concentrations of 25% of the total DNA population were successfully identified by 13 of 23, 10 of 23, and 16 of 23 labs for codons 41, 215, and 184Val, respectively. For more than 80% of those laboratories that qualitatively detected the presence of a mutation correctly, the estimated wild type/mutant ratio was less than 25% different from the input ratio in those samples containing 25 to 50% or 75% mutant input. This first multicenter study on the quality of DNA sequencing approaches for identifying HIV-1 drug resistance mutations revealed large interlaboratory differences in the quality of the results. The application of these procedures in their current state would in several cases lead to inaccurate or even incorrect diagnostic results. Therefore, proper quality control and standardization are urgently needed.
    Journal of Clinical Microbiology 08/1999; 37(7):2291-6. · 4.23 Impact Factor
Show more